Mobile

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritabprevir/Ritonavir with Ribavirin in Adults ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001477-13

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritabprevir/Ritonavir with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are to assess the safety and the percentage of subjects achieving a 12-week sustained virologic response, SVR12 [Hepatitis C Virus (HCV) ribonucleic acid (RNA) < lower limit of quantification (LLOQ) 12 weeks following treatment] of coformulated ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 with ribavirin (RBV) for 12 or 24 weeks in HCV genotype 1 (GT1)-infected adults with decompensated cirrhosis

Critère d'inclusion

  • Chronic Hepatitis C Infection

Liens